2018
Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
Sawas A, Kuruvilla J, Lue J, Deng C, Amengual J, Montanari F, Savage K, Elgedawe H, Villa D, Crump M, Connors J, O'Connor O. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience. Blood 2018, 132: 2907. DOI: 10.1182/blood-2018-99-117251.Peer-Reviewed Original ResearchAutologous stem cell transplantProgression-free survivalRefractory Hodgkin lymphomaComplete response rateDose limiting toxicitiesHigh-dose chemotherapyOverall response rateHodgkin's lymphomaBrentuximab vedotinOverall survivalDay 1Partial responseMedian numberDose levelsPrior autologous stem cell transplantResponse rateAutologous stem cell transplantationSeattle GeneticsPhase II dosePhysician's choice chemotherapyPrior radiation therapyPrior systemic therapyLong-term respondersSubset of patientsEvidence of relapse
2005
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment
Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, Della Porta M, Rumi E, Montanari F, Pascutto C, Paulli M, Lazzarino M. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leukemia Research 2005, 30: 277-282. PMID: 16112730, DOI: 10.1016/j.leukres.2005.07.006.Peer-Reviewed Original ResearchConceptsFLIPI scorePeriod of diagnosisHigh-risk groupFollicular lymphomaIntermediate riskLower riskRisk groupsMedian OSIPI scorePrognostic categoriesPoor-risk groupSubset of patientsSurvival of patientsTime of diagnosisFollicular lymphoma patientsUse of anthracyclinesDistribution of patientsType of treatmentIndependent seriesIndolent outcomeClinical characteristicsIndolent disorderPrognostic scorePrognostic indexWorse prognosis